Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
mesoblast将提交FDA申请，以治疗儿童GVHD的Ryoncil
Mesoblast Limited (NASDAQ:MESO, ASX:MSB))))), global leader in allogeneic cellular medicines for inflammatory diseases, today confirmed that it will file its Biologics License Application (BLA) for approval of Ryoncil (remestemcel-L) in the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD) with the U.S. Food and Drug Administration (FDA) next week.
全球领先的异基因细胞药物治疗炎症性疾病公司Mesoblast Limited（纳斯达克股票代码:MESO，澳大利亚证券交易所股票代码:MSB))))))证实，它将在下周向美国食品和药品管理局(FDA)提交其生物制品许可申请 (BLA)，以获得批准用于治疗类固醇难治性急性移植物抗宿主病（SR-aGVHD）患儿的Ryoncil（remestemcel-L） 。